News

Advexin is an innovative gene therapy designed to restore p53 tumor suppression that is blocked in the majority of tumors. If approved, Advexin will be the first gene

This patent is part of Tobira’s portfolio of medicines to treat infectious diseases. In addition, the company recently received a European patent for TBR-220, a second CCR5 antagonist

Based on this agreement, SymBio shall grant co-development and exclusive commercialization rights to Eisai and, in return, receive upfront and development milestone payments of up to JPY4 billion

Asuragen’s Signature NPM1 Mutations is said to be a sensitive molecular assay for the combined detection of mutations A, B and D in exon 12 of the nucleophosmin

According to the company, the Bio Mini-Revo anchor is a bioabsorbable 3.1mm diameter screw-in anchor manufactured from Conmed Linvatec’s patented self reinforced 96L/4D poly lactic acid. This unique

These approvals, in combination with the completion of transfer of the US 510k rights and validation of the manufacturing processes, enable the company to sell the ATS-manufactured product

Mr Lenz brings over 10 years of financial and operational management experience in addition to significant experience in capital raising and mergers and acquisition activities. Prior to joining

The financing was led by GE Asset Management (on behalf of the General Electric Pension Trust), with participation by Cross Creek Capital (a Wasatch Advisors company) and Integral

Fred Hassan, chairman and CEO of Schering-Plough, said: The actions announced today are part of Schering-Plough’s long-term global geographic expansion strategy. Investing in the Asia-Pacific Region, and especially